INTRODUCTION
Stem cell niche-mediated signaling is complex and context dependent. Notch signaling in hematopoiesis exemplifies this complexity 1, 2 . Osteoblasts regulate hematopoietic stem cells (HSCs) in the bone marrow niche in a Notch mediated manner, however the precise role of Notch pathway activation in HSC cell fate control is less clear 2 . In vitro, DL1 has been shown to enhance short-term SCID-repopulating cells (SRCs) and clinical data indicates that patients transplanted with cells cultured in the presence of DL1 had improved time to neutrophil engraftment following transplantation 3, 4 .
Methods to expand HSC numbers in vitro have traditionally focused on identifying self-renewal factors [4] [5] [6] [7] [8] . The phenotypic and molecular continuum between HSCs and their closely related but developmentally restricted progeny makes this endeavor challenging. We have previously shown that feedback from mature cells has a significant and cell type specific impact on HSC expansion 9, 10 . The role of lineage skewing on local and system-wide feedback may significantly contribute to the regulation of HSC fate in vitro and in vivo. Herein, we sought to understand the link between Notch-mediated mature cell lineage skewing and primitive cell fate modulation during human hematopoiesis. By decoupling intrinsic cell fate changes from their microenvironmental consequences using dynamically fed cultures 9 , we demonstrate that the myeloid cell lineage skewing observed in the presence of DL1 is predominantly attributable to Notchmediated regulation of cell type specific IL-6R expression. This lineage skewing results in an environment supportive for HSCs growth, allowing for both rapid and sustained expansion of
SCID repopulating cells (SRCs).
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METHODS

Umbilical cord blood cell collection and processing
UCB samples were collected from consenting donors according to ethically-approved procedures at Mt Sinai hospital (Toronto, ON, Canada). Mononuclear cells were obtained as described 11 .
Lineage negative (Lin -) progenitor cells or CD34 + cells were isolated from the mononuclear cell fraction using the EasySep system with the human progenitor cell enrichment kit or human CD34 + enrichment kit (Stemcell Technologies, Vancouver, BC, Canada).
DL1 preparation
DL1 was produced and coated as previously described 12 . 2.5 ug/mL of DL1 and 5 ug/mL of retronectin (Takara Shuzo, Otsu, Japan) were diluted in chilled PBS, coated onto non-tissue culture treated plates at 0.16mL/cm 2 and kept overnight at 4°C.
Cell seeding and in vitro culture
CD34
+ cells were seeded on DL1 coated plates at an initial density of 1 x 10 5 cells/mL in serum free IMDM media (Gibco, Rockville MD, USA) with 20% BIT serum substitute (Stemcell Technologies) and 1% Glutamax (Gibco). The media was supplemented with 100ng/mL Stem Cell Factor (SCF, R&D Systems, Minneapolis, MN, USA), 100 ng/mL FMS-like Trysine Kinase 3 Ligand (FL, R&D Systems), 50ng/mL Thrombopoietin (TPO, R&D Systems), and 1 ug/mL low-density lipoproteins (LDL, Calbiochem, LaJolla, CA, USA). Plates were cultured on an orbital shaker to aid in mixing of the system. To mimic the feeding scheme of the previously described fed-batch system 9 , cultures were fed every 24 h with one unit volume of fresh media, to maintain a dilution rate of D=1. Cells were transferred to plates with freshly coated ligand
For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From every 4 days. Where indicated, IL-6 (R&D) was used at 50 ng/mL, sIL-6R (R&D) was used at 1000 ng/mL, JAKi (Calbiochem) was used at 50 nM, γ -secretase inhibitor L685,458 (GSi, R&D) was used at 1 μ M, and SR1 was used at 750 nM. For non-fed-batch conditions, CD34 + cells were cultured at 1 x 10 5 cells/mL, and a full media exchange was performed every 4 days.
Cell assays
CFC and LTC-IC assays were performed as previously described 11 . Surface marker staining was performed with conjugated human antibodies (BD Biosciences, San Jose CA, USA FACSAria flow cytometer (BD Biosciences), as previously described 13 . 40 sorted cells were dispensed per well in a 96-well plate in the above described media and cultured for 7 days. For the assessment of paracrine signaling, conditioned media was produced by culturing Lin -cells for 10 days in the above described culture media and then sorting for cells positive for CD14, CD15, CD7, CD41, GlyA or other (CD34   -CD14   -CD15   -CD7  -CD41 -GlyA -). Mature cells were seeded at 5 x 10 5 cells/mL for 7 days and the media was then collected and used to culture the sorted primitive cells as above.
Gene Expression Analysis
Raw gene expression data were obtained from the NCBI's Gene Expression Omnibus (GEO) through accession number GSE42414 14 and GSE24759 15 . The two datasets were combined by following a 4-step procedure. First, quantile signals of GSE42414 and GSE24759 datasets were obtained using the normalizeQuantiles() function and the justRMA() function in the limma package (v3.12.3) of BioConductor, respectively. Second, genome-wide normalization was performed with respect to a common population between the two. Third, for each dataset, the average value of probes that target the same gene was calculated. Lastly, the two datasets were combined through Entrez ID. All the analyses were performed in R. Cell populations were simulation, starved cells were transferred to plates pre-coated with DL1 (2.5ug/mL) to initiate the stimulation period. After the commencement of stimulation, cells were fixed and permeabilized as previously described 16 , before being stained with pSTAT3 antibody (Cell Signaling Technology, Danvers MA, USA) and an AF-647 secondary antibody.
Secreted factor analysis
Conditioned media from cells cultured for 12 days in the indicated conditions was collected and frozen. Secreted factor concentrations were sampled in duplicate from thawed conditioned media aliquots using IL-6 and sIL-6R Quantikine ELISA Kits (R&D Systems, Minneapolis MN, USA), according to the manufacturer's directions.
Limiting dilution transplantation studies
All animal studies were performed according to procedures approved by appropriate animal 
Mathematical simulations
The model that we previously developed and described 9, 11 was used to run all culture simulations with MATLAB 2012 software (Mathworks, Natick MA, USA). For specific revisions to the model made for this study, see supplementary information.
Statistical Analysis
Statistical significance was computed using student t-test and ANOVA. All error bars represent the standard deviation of three or more biological replicates. Asterisks (*) or number signs (#)
indicate statistical significance between indicated conditions (or if not indicated, between the test condition and control) of p<0.05.
RESULTS
DL1 mediated lineage skewing creates a blood progenitor cell supportive environment.
Immobilized DL1 was added to a fed-batch culture platform, which regulates endogenously produced soluble factors 9 . The addition of DL1 caused a significant increase in primitive cells, as measured both by phenotype (CD34 + and CD34 + CD90 + ) and by functional in vitro assays (colony forming cell (CFC) assay and long term culture-initiating cell (LTC-IC) assay) ( Figure   1A ). The greatest impact of the ligand was seen on the more primitive progenitor populations (CD34 + CD90 + and LTC-IC). During the first several days of culture, we observed that DL1 caused a decrease in total cell number due to slower proliferation, as demonstrated by CFSE staining ( Figure S1 ). In this heterogeneous culture system, there was not an immediate enhancement in the frequency of progenitor cells, as compared to the control; however, as the culture progressed, the anticipated DL1-mediated enhancement of primitive progenitors emerged. We have previously demonstrated that endogenously produced secreted factors can be dominant modulators of HSC fate 9, 17 . Thus, given the delayed emergence of progenitor expansion with DL1, we next examined whether DL1 was altering the endogenous microenvironment to indirectly regulate primitive cell fate.
To decouple the direct and indirect effects of DL1, we compared the observed impact of DL1 on (Figure 1Bi ). In contrast, DL1 added to the CD34 + input cell population gave a CD34 + CD90 + cell expansion significantly higher than the control population after 16 days of culture ( Figure 1Bii ). These data suggest that DL1 is not exclusively targeting HSC selfrenewal. Instead, we hypothesised that DL1 is acting (at least in part) non-cell autonomously with respect to HSC fate.
In order to help determine which lineage populations may be receptive to DL1 and responsible for the indirect enhancement of primitive progenitor cells, we mined gene expression datasets of sorted hematopoietic populations 14, 15 to assess the expression levels of Notch1 and Notch2, the known receptors of DL1 19 . Both of these receptors were expressed at varying levels on many hematopoietic cell populations with particular enrichment on myeloid progenitors (Figure 1Ci) , suggesting lineage committed cell populations as targets of DL1. Protein expression analysis of Notch1 and Nocth2 also show variation in their expression among both primitive and lineagerestricted populations ( Figure S2 ). It has previously been reported that DL1 changes mature lineage output 3, 20 . We predicted that this lineage skewing may be altering the cell environment and contributing to the effects seen on primitive progenitor expansion. The addition of DL1 to CD34 + cells led to a significant and sustained reduction in the production of CD14 + monocytes and CD15 + granulocytes and an increase in CD7 + lymphocytes, as has been previously reported 3 ( Figure 1D ).The reduction of CD14 + and CD15 + cells seen with the addition of DL1 is particularly interesting as it has been shown that mature myeloid cells have a significant inhibitory effect on the expansion of progenitor populations 10, 21 .
To assess the feedback signaling impact of specific mature cell populations on HSC cell fate, we We next sought to identify the downstream targets through which DL1-mediated signaling was altering myeloid cell production.
DL1 activates JAK-STAT3 signaling but inhibits IL-6 cis-signaling.
Given the inhibitory nature of CD14 + and CD15 + cells, we were particularly interested in understanding the mechanism by which DL1 inhibited their production. The production and differentiation of macrophages and granulocytes is known to be largely modulated by gp130
signaling and cytokine-mediated STAT3 activation [22] [23] [24] [25] . Furthermore, interactions between Notch signaling and STAT3 activation have been reported 26, 27 , leading us to hypothesize that the DL1-mediated effect on myeloid cell production acted through modulation of the JAK-STAT3 signaling pathway.
To investigate the impact of DL1 on STAT3, we measured the dynamic activation of STAT3 in response to different stimuli. As expected, stimulation of cultured CD34 + cells with IL-6 or both IL-6 and sIL-6R caused a significant and JAK-dependent up-regulation of pSTAT3 ( Figure   2Ai ). When cultured CD34 + cells were stimulated with DL1, we saw a rapid activation of STAT3 that mimicked that seen with IL-6 and sIL-6R (Figure 2Aii ). This activation could be prevented by either JAKi or γ -secretase inhibitor (GSi). However, the addition of cycloheximide did not impact the DL1-mediated activation of STAT3, which together with the rapid kinetics of the activation, suggested that it is not a transcriptionally regulated event. The JAK-STAT pathway is known to act in an auto-regulatory manner, such that targets of STAT3 up-regulate the further production of IL-6 and related ligands 28 . Accordingly, we measured the levels of soluble IL-6 family members during culture with or without DL1 and observed that CD34 + cells cultured in the presence of DL1 produced significantly higher concentrations of both IL-6 and sIL-6R ( Figure 2B) . Notably, DL1-mediated IL-6 production was abrogated by the addition of a JAK inhibitor. Conversely, levels of sIL-6R were only somewhat dampened by a JAK inhibitor,
suggesting that the DL1-mediated increases in sIL-6R were at least partially JAK-STAT3 independent.
Our observation that DL1 was modulating IL-6 signaling led us to consider whether DL1 was also changing the population of cells that were responsive to IL-6. IL-6 can initiate JAK-STAT signaling in one of two ways ( Figure 2C ). IL-6 cis-signaling results when the IL-6 ligand binds to the mIL-6R, which then associates with gp130. In hematopoiesis, mIL-6R and IL-6 cissignaling are restricted to myeloid lineage cells 29 , and we observed that the addition of IL-6 to CD34 + cells produced a significant and JAK-dependent increase in CD14 + and CD15 + cell production ( Figure 2D, Figure S4A ). In contrast, combining exogenous IL-6/sIL-6R with DL1
produced the same low levels of CD14 + and CD15 + cells that were generated with DL1 alone, indicating that DL1 is impeding IL-6 cis-signaling. In cells that do not express mIL-6R, IL-6 trans-signaling can occur when IL-6 binds to sIL-6R, and the soluble complex then binds to the ubiquitously expressed gp130 receptor. When both IL-6 and sIL-6R were added to culture, in addition to the increase in CD14 + and CD15 + cells, we also observed a trans-signaling-mediated increase in GlyA + cells (Figure 2D) , consistent with previous reports 30 . DL1 in combination with IL-6/sIL-6R maintained GlyA + levels, suggesting IL-6 trans-signaling is not affected by DL1.
The addition of IL-6 or IL-6/sIL-6R led to a significant increase in total cell expansion but a corresponding decrease in the frequency of CD34 + cells ( Figure S4B) . Notably, on the primitive Therefore, despite the similar propensities of DL1 and IL-6/sIL-6R to activate STAT3, these two stimuli produce very different effects on both mature cell and primitive cell populations. It was puzzling that both DL1 and IL-6/sIL-6R activated STAT3 but that the effects of the signaling resulted in completely different cell population dynamics. We hypothesized that the reduction of IL-6 cis-signaling was a result of the loss of mIL-6R. To test this hypothesis, we next measured the effect of DL1 on cell population specific mIL-6R expression.
DL1 converts progenitors from IL-6 cis-signaling to trans-signaling through loss of mIL-
6R.
Freshly isolated CD34
+ cells do not express mIL-6R, however, upon culture, mIL-6R expression was very quickly (within 6h) up-regulated ( Figure 3A) . In the presence of DL1, mIL-6R upregulation was significantly inhibited. This inhibition occurred rapidly, before the first cell division, suggesting that this effect is signaling mediated, as opposed to due to the emergence of a new cell population or due to changes in cell population composition. The rapid DL1-mediated mIL-6R inhibition was seen on both the more primitive CD34 + CD45RA -cell population and the more committed CD34 + CD45RA + cell population (Figure 3Ai,ii) . A similar trend was seen on the highly purified CD34 + CD38 -CD45RA -CD90 + population ( Figure S5A ). Throughout culture, CD34 + cells maintained mIL-6R at a significantly lower frequency in the presence of DL1 (Figure 3B,C) . This was true on both the CD34 + CD45RA -subset and the CD34 + CD45RA + subset ( Figure 3D ). The addition of either exogenous IL-6/sIL-6R or a JAK inhibitor did not significantly alter the levels of mIL-6R seen with or without DL1 on the CD34 + cells,
demonstrating that the inhibition of mIL-6R expression was occurring via a JAK-STAT3
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From independent mechanism (Figure 3B) , consistent with the JAK-STAT3 independent sIL-6R production observed in DL1 culture (Figure 2Bii) . Conversely, the DL1 mediated effect was significantly diminished in the presence of the γ -secretase inhibitor ( Figure S5B ).
Studies have shown that CD34
+ mIL-6R + cells are myeloid-restricted progenitors 20 . Therefore, the reduction of mIL-6R on these cells prevents IL-6 cis-signaling-mediated production of mature monocytes and granulocytes. In the absence of mIL-6R, myeloid progenitor cells can still respond to IL-6 via IL-6 trans-signaling in the presence of sIL-6R. However, our use of the fedbatch culture platform, which allowed for the continuous reduction of the impact of endogenously produced soluble signaling factors, allowed us to decouple these aspects by reducing sIL-6R levels ( Figure 3E ) and thus enhancing the impact of DL1-mediated mIL-6R
inhibition. It is likely that DL1 causes the ADAM17-mediated shedding of mIL-6R, as the metalloprotease ADAM17 is known to facilitate mIL-6R shedding 31 , and is also responsible for the cleavage of the extracellular domain of Notch receptors in order to activate Notch signaling 32 . Cell surface ADAM17 is upregulated on cells cultured in the presence of DL1
( Figure 3F) . Moreover, intracellular accumulation of mIL-6R is not affected by DL1, providing further evidence that the reduction in mIL-6R is due to receptor shedding and not internalization ( Figure 3G ).
Taken together, these data indicate that both DL1 and IL-6/sIL-6R activate the JAK-STAT3
pathway. Activation through IL-6/sIL-6R leads primarily to IL-6 cis-signaling which enhances production of CD14 + and CD15 + cells, and results in the generation of a non-supportive microenvironment with high levels of feedback inhibition. Conversely, DL1 supplementation causes the JAK-STAT3 independent reduction of mIL-6R expression, which inhibits IL-6 cissignaling. As a result, DL1-mediated STAT3 activation results only in IL-6 trans-signaling, which can be minimized through environmental regulation of sIL-6R with the fed-batch culture system. Together, this results in a decrease in CD14 + and CD15 + cell production, which generates a more supportive environment for progenitor cell expansion. A summary model of the system is shown in Figure 3H . Given the degree of environmental control that DL1
generates in combination with the fed-batch platform, we further hypothesized that this system would support the production of both short-term and long-term HSCs.
Concurrent modulation of IL-6 cis-and trans-signaling supports the expansion of shortterm and long-term SRCs
To predict the impact of DL1 addition on HSC fate control, we first used a previously described mathematical model 9, 11 . The model inputs were revised based on DL1 specific data (details of the mathematical model are described in the supplementary text). Figure 4A shows that the predicted population outputs were comparable to experimental controls, demonstrating the utility of the model in predicting outputs from DL1 or IL-6/sIL-6R conditions. One prediction that emerged from the model simulations was that the combination of the fed-batch system and DL1
would lead to significant expansions of both short-term and long-term repopulating HSCs, as measured by SRCs ( Figure 4B ). The expansion of primitive progenitors and short-term repopulating HSCs by DL1 has been previously demonstrated, by quantification of human engraftment at 3 weeks and 9 weeks post-transplantation 4 . This study did not see a significant expansion of the longer-term repopulating HSCs with DL1. However, the fed-batch system reduces IL-6 trans-signaling and produces a different microenvironmental context onto which DL1-induced Notch signaling is added.
To experimentally assess the expansion of the SRC populations, we transplanted cells expanded with or without DL1 into NSG mice, and quantified human cell repopulation in the bone marrow intermittently for 24 weeks. We confirmed that DL1 showed a trend towards enhancement of human engraftment at 3-and 9-weeks post-transplantation ( Figure 4C) . We then assessed longer-term SRC expansion by limiting dilution analysis at 16-weeks post-transplantation ( Figure 4D , Table S2 ). The combination of fed-batch and DL1 led to a significant expansion of
SRCs as compared to the uncultured CD34 + cells. Thus, the environmental regulation gained with the combination of DL1 and the fed-batch feeding strategy allowed for both rapid and sustained human engraftment, as illustrated schematically in Figure 4E . Taken together, the findings in this study demonstrate a novel mechanism for signaling rewiring through the conversion of IL-6 cis-signaling to IL-6 trans-signaling, thereby altering the cell populations that are responsive the JAK-STAT pathway. This regulation generates a supportive soluble factor microenvironment that enables enhanced expansion of stem and progenitor cells.
DISCUSSION
Notch signaling plays many important roles in human hematopoiesis, including the in vitro enhancement of primitive cell expansion, which can be achieved through presentation of immobilized DL1 ligand at low concentrations. However, the mechanisms through which this effect is achieved, and why it had been limited to short-term SRCs were not fully understood.
Here, we demonstrate a non stem cell autonomous role whereby DL1 acts to alter cell specific
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responsiveness to IL-6 signaling, subsequently reducing inhibitory myeloid cell production and unmasking a signaling environment supportive of HSC expansion.
Despite similar STAT3 activation by DL1 and IL-6/sIL-6R, the resulting impact of these two stimuli on mature cell populations was very different. We hypothesized that this difference was due to the modulation of IL-6 signaling at the level of mIL-6R and we showed that the addition of DL1 causes the loss of mIL-6R from CD34
+ myeloid progenitor cells, thus preventing IL-6 cis-signaling. Our data indicate that DL1 signaling is altering mIL-6R receptor expression in individual cells; however, we cannot formally rule out mIL-6R differences resulting from changes in relative numbers of highly enriched stem cell populations.
It is likely that the Notch pathway impacts lineage differentiation via a number of different mechanisms, including the alteration of Cebpa expression on primitive myeloid cells 33 + CD45RA -and (ii) CD34 + CD45RA + cells. E) Fed-batch (FB) conditions reduced sIL-6R production as compared to non-fed-batch conditions. F) Protein expression of ADAM17 measured by flow cytometry on cells cultured in the absence or presence of DL1 for 10-12 days. G) Comparison of (i) surface expression of mIL-6R (CD126) and (ii) intracellular expression of mIL-6R, on cells cultured in the absence or presence of DL1 for 8-12 days. H) Schematic of proposed mechanism. DL1 activates STAT3 and causes the loss of mIL-6R. The loss of mIL-6R reduces IL-6 cis-signaling, and thus reduces the production of CD14 + and CD15 + . Instead, only IL-6 trans-signaling can occur, which enhances the production of other cell types, and results in a microenvironment that is more supportive for HSPCs. The fed-batch conditions further reduce IL-6 trans-signaling. All error bars indicate standard deviation. n ≥ 3, * = p < 0.05. For personal use only. on August 31, 2017 . by guest
